Previous research has reported that VDAC1 is a pan-cancer target, which is significantly overexpressed in breast cancer, cervical squamous cell carcinoma, pancreatic cancer, lung adenocarcinoma and melanoma, and the upregulation of VDAC1 is significantly associated with poor prognosis (Wang et al. 2022). Here, VDAC1 is linked to breast cancer.